Aiosyn and Physiogenex partner to enhance kidney disease drug development
Figure 1. Illustration of the NephroPath platform’s capabilities in performing automated quantification and multi-class prediction on an entire rat kidney cortex. Notable classes: normal tubuli (orange), atrophic/dilated tubuli (green/red), glomeruli (pink), abnormal/sclerotic glomeruli (dark blue), arteries (light blue), interstitium (not colored).
Nijmegen, The Netherlands – Aiosyn, a pioneering medical software company specializing in AI-powered pathology solutions for cancer and kidney disease, has announced a collaboration with Physiogenex, a leading preclinical Contract Research Organization (CRO) specializing in metabolic diseases.
“The combination of Aiosyn’s NephroPath platform and the preclinical models and research capabilities of Physiogenex enables us to provide our biopharma customers with unique and more comprehensive insights to support them in accelerating renal drug development studies.”
Patrick de Boer, CEO of Aiosyn
Aiosyn’s Kidney Image Analysis Services, provided through its NephroPath platform, enable automated assessment and quantification of whole kidney tissue. The algorithms identify and quantify key structures such as normal and abnormal tubuli, standard and sclerotic glomeruli, and interstitium, offering detailed, reproducible, and fast insights. Aiosyn’s solutions can additionally undergo tailored training to identify key structures aligned with specific project requirements.
Physiogenex has been developing innovative CRO preclinical services and animal models to evaluate the efficacy of drugs targeting metabolic diseases, including Chronic Kidney Diseases (CKD). “The Aiosyn NephroPath platform now provides a wonderful tool to better quantify kidney lesions in our animal models of CKD. This new AI-powered imaging technology delivers a greater sensitivity to detect the drugs’ efficacy. Keeping in mind the translational aspect of Aiosyn’s NephroPath, this will help our clients to expedite their development programs towards the clinics.” said Dr. Thierry Sulpice, CEO/CSO of Physiogenex.
Aiosyn and Physiogenex share a commitment to enhance the diagnosis, research, and management of kidney diseases. Through this collaboration, both organizations aim to leverage their expertise, resources, and technologies to elevate current preclinical research even further.
A recent preclinical study carried out between the two companies has shown the effectiveness of the NephroPath platform in segmenting kidney tissue classes (Figure 1.) and quantifying glomerulosclerosis and tubular damage on whole rat kidneys. A positive correlation was observed between glomerulosclerosis, tubular scores, and kidney damage across all groups. Further results will be presented at the CKD Summit in Boston from March 19th to March 21st.
Partnering with Physiogenex marks the next step in Aiosyn’s development in the renal field. With this collaboration and the recent launch of the NephroPath platform, Aiosyn reaffirms its commitment to elevating the assessment of (pre)clinical kidney samples.
About Aiosyn
Aiosyn is a Dutch company that develops precision pathology software for cancer and kidney disease. Aiosyn’s solutions are integrated into standard pathology workflows. The Aiosyn team has been built upon more than 20 years of research experience in the field of pathology and is rooted into the pathology practice.
About Physiogenex
Physiogenex is one of the leading CRO companies specializing in preclinical studies for metabolic diseases. It works with over 100 biopharmaceutical companies all around the world. Physiogenex has been on the market for more than 20 years, driving the performance of innovative biotechs and some of the biggest pharmaceutical companies in the world. Its areas of interest include, but are not limited to, fibrosis and diabetic nephropathy.
SOURCE: Aiosyn
